Abstract
An α1a – and α1d – adrenergic receptor (AR) selective antagonist may be a more efficacious treatment for BPH/LUTS patients and may have fewer side effects than the existing pharmaceuticals. A facile synthesis for a series of (2-cyclopropoxyphenyl)piperidine derivatives has been developed, in which aryl vinyl ether formation and subsequent cyclopropyl formation provide efficient access to key intermediate N-Boc-4-(2-cyclopropoxyphenyl)piperidine. The synthesized (2-cyclopropoxyphenyl)piperidine derivatives display high affinity and selectivity for α1a – AR and α1d – AR compared to α1b-AR and D2 receptor, Ki values for α1a-AR are 0.91 nM to 79.0 nM and α1d-AR are 2.0 nM to 57 nM; Ki values for α1b-AR are 107 nM to 839.8 nM and D2 receptor are 66.2 nM to 187.1 nM. The selectivity ratios of Ki(α1b)/Ki(α1a) are 11 to 155 fold, Ki(α1b)/Ki(α1d) are 6 to 171 fold, Ki(D2)/Ki(α1a) are 2 to 158 fold, and Ki(D2)/Ki(α1d) are 1.2 to 89 fold. Compound 17a shows improved stability in human liver microsome test (t1/2 = 18 minutes).
Keywords: Synthesis, piperidine Derivatives, Receptor Inhibitors, microsome test, 8-methoxyfluoroquinolone
Medicinal Chemistry
Title: Synthesis, In Vitro Activities of (2-Cyclopropoxyphenyl)piperidine Derivatives for α1a and α1d Adrenergic Receptor Inhibitors
Volume: 5 Issue: 1
Author(s): Shengjian Li, George Chiu, Virginia L. Pulito, Jingchun Liu, Peter J. Connolly and Steven A. Middleton
Affiliation:
Keywords: Synthesis, piperidine Derivatives, Receptor Inhibitors, microsome test, 8-methoxyfluoroquinolone
Abstract: An α1a – and α1d – adrenergic receptor (AR) selective antagonist may be a more efficacious treatment for BPH/LUTS patients and may have fewer side effects than the existing pharmaceuticals. A facile synthesis for a series of (2-cyclopropoxyphenyl)piperidine derivatives has been developed, in which aryl vinyl ether formation and subsequent cyclopropyl formation provide efficient access to key intermediate N-Boc-4-(2-cyclopropoxyphenyl)piperidine. The synthesized (2-cyclopropoxyphenyl)piperidine derivatives display high affinity and selectivity for α1a – AR and α1d – AR compared to α1b-AR and D2 receptor, Ki values for α1a-AR are 0.91 nM to 79.0 nM and α1d-AR are 2.0 nM to 57 nM; Ki values for α1b-AR are 107 nM to 839.8 nM and D2 receptor are 66.2 nM to 187.1 nM. The selectivity ratios of Ki(α1b)/Ki(α1a) are 11 to 155 fold, Ki(α1b)/Ki(α1d) are 6 to 171 fold, Ki(D2)/Ki(α1a) are 2 to 158 fold, and Ki(D2)/Ki(α1d) are 1.2 to 89 fold. Compound 17a shows improved stability in human liver microsome test (t1/2 = 18 minutes).
Export Options
About this article
Cite this article as:
Li Shengjian, Chiu George, Pulito L. Virginia, Liu Jingchun, Connolly J. Peter and Middleton A. Steven, Synthesis, In Vitro Activities of (2-Cyclopropoxyphenyl)piperidine Derivatives for α1a and α1d Adrenergic Receptor Inhibitors, Medicinal Chemistry 2009; 5 (1) . https://dx.doi.org/10.2174/157340609787049280
DOI https://dx.doi.org/10.2174/157340609787049280 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Current Medicinal Chemistry Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer
Current Pharmaceutical Biotechnology Performance of Feature Selection Methods
Current Genomics Vitamin D Receptor is a Novel Drug Target for Ovarian Cancer Treatment
Current Cancer Drug Targets Editorial [Hot Topic: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy (Guest Editor: Marie Ranson)]
Current Drug Targets Electrospun Biodegradable Bi-Layered Microfiber Membranes for Aluminum Removal from Drinking Water
Micro and Nanosystems Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry STAT3 Regulation of Glioblastoma Pathogenesis
Current Molecular Medicine Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products
Current Neuropharmacology Thermal [3+2] Cycloaddition Reaction of N-Acyliminophenanthridinium Betaine with Allenoates: Facile Access to Phenanthridine-fused Tetracyclic Heterocycles
Letters in Organic Chemistry The Role of Estrogen and Estrogen Receptors in Chemoresistance
Current Medicinal Chemistry Recent Advances on Small-Molecule Survivin Inhibitors
Current Medicinal Chemistry The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets